Liabilities / Assets
71st percentile
Higher debt load relative to assets than 71% of similar nonprofits.
Simmaron Research Inc.
990 • Fiscal year 2023 • EIN 45-2191464
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.14x
Liabilities / Revenue
52nd percentile
Higher debt load relative to revenue than 52% of similar nonprofits.
Net Margin
27th percentile
Higher net margin than 27% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
3rd percentile
Faster asset growth than 3% of similar nonprofits.
Revenue Growth
92nd percentile
Faster revenue growth than 92% of similar nonprofits.
Balance Sheet
Assets
Down$121,145
Down $129,052 (-52%) from 2022
Net Assets
Down$104,331
Down $51,218 (-33%) from 2022
Liabilities
Down$16,814
Down $77,834 (-82%) from 2022
Revenue And Expenses
Revenue
Up$626,336
Up $328,963 (+111%) from 2022
Expenses
Up$677,554
Up $364,430 (+116%) from 2022
Net Income
Down-$51,218
Down $35,467 (-225%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
To conduct research on the etiology, pathogenesis, biomarkers, and treatment of myalgic encephelomyelitis (me) formerly know as chronic fatigue syndrome (cfs). Our mission statement is to scientifically redefine me/cfs.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $121,145
- Liabilities
- $16,814
- Net assets
- $104,331
- Revenue
- $626,336
- Expenses
- $677,554
- Net income
- -$51,218